Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
150.78 x 5 151.11 x 1
Pre-market by (Cboe BZX)
152.15 -0.72 (-0.47%) 01/31/25 [NYSE]
150.78 x 5 151.11 x 1
Pre-market 150.90 -1.25 (-0.82%) 05:00 ET
News & Headlines for Fri, Jan 31st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Is Johnson & Johnson Stock a Buy?

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However, Johnson & Johnson...

JNJ : 152.15 (-0.47%)
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?

Johnson & Johnson (NYSE: JNJ) has a diverse healthcare business, and investors often look to it as a safe dividend stock to invest in for the long term. One area where it has been lacking, however, is...

JNJ : 152.15 (-0.47%)
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?

Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year.

JNJ : 152.15 (-0.47%)
KVUE : 21.29 (-1.98%)
AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs

AbbVie Inc. ABBV reported fourth-quarter 2024 adjusted earnings of $2.16 per share, which beat the Zacks Consensus Estimate of $2.13. The reported earnings also exceeded the company’s guidance of $2.06-$2.10...

JNJ : 152.15 (-0.47%)
ABBV : 183.90 (+4.70%)
RHHBY : 39.2500 (-1.48%)
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of the disease.This...

JNJ : 152.15 (-0.47%)
MRK : 98.82 (-0.13%)
UTHR : 351.17 (-0.32%)
Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates

Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates

JNJ : 152.15 (-0.47%)
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 70 cents. Adjusted earnings declined 29% year over...

JNJ : 152.15 (-0.47%)
TEVA : 17.73 (-0.62%)
ABBV : 183.90 (+4.70%)
SNY : 54.34 (+0.35%)
2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

NVDA : 120.07 (-3.67%)
$SPX : 6,040.53 (-0.50%)
JNJ : 152.15 (-0.47%)
PG : 165.99 (-0.85%)
KVUE : 21.29 (-1.98%)
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?

AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $14.92 billion...

JNJ : 152.15 (-0.47%)
ABBV : 183.90 (+4.70%)
RHHBY : 39.2500 (-1.48%)
3 Stocks Upgraded by Bank of America – Here's Why They're Bullish

Bank of America analysts have recently shifted their views on these three stocks, leaving investors with a few points to consider.

NFLX : 976.76 (+0.36%)
V : 341.80 (-0.36%)
JNJ : 152.15 (-0.47%)

Barchart Exclusives

What Were Long-Term Monthly Charts Showing at the End of January?
From a long-term investment point of view, the value of technical analysis may be diminishing, as indicated by the end of January monthly charts. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Exclusive Barchart Webinar: Unlock the Power of High-Accuracy Option Trading